Reading TELA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELA free→Reading TELA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELA free→QuarterlyIQ Insights · TELA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, at the 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of TELA Bio, Inc. (the “ Company ”), the Company’s stockholders approved the amendment (the “ Plan Amendment ”) to the Company’s Amended and Restated 2019 Equity Incentive Plan, as amended (the “ A&R 2019 Plan ”), to, among other things, increase the authorized sha…
Results of Operations and Financial Condition. On May 12, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to th…
Results of Operations and Financial Condition. On April 29, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million. The Company has not yet completed its quarter-end close processes for the quarter ended March 31, 2026. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based upon information available to managemen…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board, including the Compensation Committee o…
Results of Operations and Financial Condition. On March 24, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The…
Termination of a Material Definitive Agreement. In connection with the entry into the Credit Agreement, the Company’s Credit and Security Agreement, dated as of May 26, 2022, with MidCap Financial Trust (“ MidCap ”) was terminated, effective as of the Funding Date, and MidCap’s security interest in the Company’s assets and property was released.
Unregistered Sales of Equity Securities. The information set forth under Item 1.01(a) of this Current Report on Form 8-K with respect to the Warrants is incorporated by reference into this
Entry into a Material Definitive Agreement. (a) Entry into Perceptive Term Loan Facility On November 13, 2025 (the “ Signing Date ”), TELA Bio, Inc. (the “ Company ”) entered into a Credit Agreement and Guaranty (the “ Credit Agreement ”) with Perceptive Credit Holdings V, LP, as lender and administrative agent (“ Perceptive ”), which provides for a senior secured term loan facility in an aggregate principal amount of up to $70.0 million (the “ Perceptive Term Loan Facility ”). An initial loa…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01(a) of this Current Report on Form 8-K is incorporated by reference into this
Results of Operations and Financial Condition. On November 13, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subj…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2025, the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed William Plovanic to serve as a Class I director, with a term expiring at the Company’s 2026 An…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On October 4, 2025, Lisa Colleran, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered her resignation from the Board, effective as of October 4, 2025. Ms. Colleran also resigned from her positions as a member of the Nominating and Corporate Governance Committee and the Audit Comm…
Results of Operations and Financial Condition. On August 11, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On May 30, 2025, Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025. Mr. Blizard also resigned from his position as a member of the Nominating and Corporate Governance Committee. Mr. Blizard’s decision…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 28, 2025, at the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) of TELA Bio, Inc. (the “ Company ”), the Company’s stockholders approved the amendment (the “ Plan Amendment ”) to the Company’s Amended and Restated 2019 Equity Incentive Plan (the “ A&R 2019 Plan ”) to, among other things, increase the authorized shares issuable…
Results of Operations and Financial Condition. On May 8, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the…
Results of Operations and Financial Condition. On March 20, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter of 2024 and the fiscal year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.